Clinical trials: Achalasia
Achalasia
Study of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Type I or II Achalasia
The objectives of this study are as follows: In participants with primary Type I or II achalasia, following a single 5-mg dose of olinciguat (IW-1701), To assess the safety and tolerability To determine the effects on measures of…
- Trial name
- NCT02931565
- Testing
- Olinciguat
- Where
- 5 sites in United States
- Volunteers
- 9 people
- Sponsor
- Cyclerion Therapeutics